PURPOSE: To evaluate the impact of primary Gleason grade in Gleason score (GS) 7 prostate cancer on biochemical recurrence (BCR) after radical prostatectomy in Korean men. MATERIALS AND METHODS: We retrospectively reviewed records of 1,026 patients who underwent radical prostatectomy at Seoul National University Bundang Hospital between November 2003 and June 2009. We excluded patients who had received neoadjuvant therapy and had positive resection margins. Finally, 295 and 113 patients with GS 3+4 and GS 4+3, respectively, were included in this study. All patients were followed for at least 2 years. RESULTS: Of the 408 GS 7 patients, 295 (72.3%) were 3+4 and 113 (27.7%) were 4+3. Mean serum prostate specific antigen level in primary Gleason 3 was 8.99 ng/ml and primary Gleason 4 was 11.11 ng/ml. Patients with GS 4+3 were more likely to have extracapsular extension (30.1% vs. 17.6%, p<0.010) and lymphatic invasion (16.8% vs. 7.1%, p<0.005). After 2 years follow up BCR was detected in a total of 40 patients. In GS 7 with primary Gleason 3, BCR occurred in 15 (5.08%) patients while 20 (17.70%) showed BCR in GS 7 with primary Gleason 4. CONCLUSIONS: In this study of a large, single center cohort of Korean men with GS 7 prostate cancer a noticeable difference in BCR was seen. Primary Gleason grade 4 have a higher risk of BCR compared to primary Gleason grade 3. This information may be useful when counseling patients on their prognosis and further management options.
PURPOSE: To evaluate the impact of primary Gleason grade in Gleason score (GS) 7 prostate cancer on biochemical recurrence (BCR) after radical prostatectomy in Korean men. MATERIALS AND METHODS: We retrospectively reviewed records of 1,026 patients who underwent radical prostatectomy at Seoul National University Bundang Hospital between November 2003 and June 2009. We excluded patients who had received neoadjuvant therapy and had positive resection margins. Finally, 295 and 113 patients with GS 3+4 and GS 4+3, respectively, were included in this study. All patients were followed for at least 2 years. RESULTS: Of the 408 GS 7 patients, 295 (72.3%) were 3+4 and 113 (27.7%) were 4+3. Mean serum prostate specific antigen level in primary Gleason 3 was 8.99 ng/ml and primary Gleason 4 was 11.11 ng/ml. Patients with GS 4+3 were more likely to have extracapsular extension (30.1% vs. 17.6%, p<0.010) and lymphatic invasion (16.8% vs. 7.1%, p<0.005). After 2 years follow up BCR was detected in a total of 40 patients. In GS 7 with primary Gleason 3, BCR occurred in 15 (5.08%) patients while 20 (17.70%) showed BCR in GS 7 with primary Gleason 4. CONCLUSIONS: In this study of a large, single center cohort of Korean men with GS 7 prostate cancer a noticeable difference in BCR was seen. Primary Gleason grade 4 have a higher risk of BCR compared to primary Gleason grade 3. This information may be useful when counseling patients on their prognosis and further management options.
Authors: Cristina Magi-Galluzzi; Andrew J Evans; Brett Delahunt; Jonathan I Epstein; David F Griffiths; Theo H van der Kwast; Rodolfo Montironi; Thomas M Wheeler; John R Srigley; Lars L Egevad; Peter A Humphrey Journal: Mod Pathol Date: 2010-08-27 Impact factor: 7.842
Authors: Daniel M Berney; Thomas M Wheeler; David J Grignon; Jonathan I Epstein; David F Griffiths; Peter A Humphrey; Theo van der Kwast; Rodolfo Montironi; Brett Delahunt; Lars Egevad; John R Srigley Journal: Mod Pathol Date: 2010-09-03 Impact factor: 7.842
Authors: Hemamali Samaratunga; Rodolfo Montironi; Lawrence True; Jonathan I Epstein; David F Griffiths; Peter A Humphrey; Theo van der Kwast; Thomas M Wheeler; John R Srigley; Brett Delahunt; Lars Egevad Journal: Mod Pathol Date: 2010-09-10 Impact factor: 7.842
Authors: Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson Journal: J Urol Date: 2011-01-15 Impact factor: 7.450
Authors: Jonathan L Wright; Claudia A Salinas; Daniel W Lin; Suzanne Kolb; Joseph Koopmeiners; Ziding Feng; Janet L Stanford Journal: J Urol Date: 2009-12 Impact factor: 7.450
Authors: Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Qi Long; Jianpeng Xu; Adeboye O Osunkoya; Soma Sannigrahi; Brent A Johnson; Wei Zhou; Theresa Gillespie; Jong Y Park; Robert K Nam; Linda Sugar; Aleksandra Stanimirovic; Arun K Seth; John A Petros; Carlos S Moreno Journal: Cancer Res Date: 2014-04-08 Impact factor: 12.701
Authors: M Salemi; A Galia; F Fraggetta; C La Corte; P Pepe; S La Vignera; G Improta; P Bosco; A E Calogero Journal: Eur J Histochem Date: 2013-04-15 Impact factor: 3.188
Authors: Anthony D Ta; Nathan P Papa; Nathan Lawrentschuk; Jeremy L Millar; Rodney Syme; Graham G Giles; Damien M Bolton Journal: Prostate Int Date: 2015-07-17
Authors: Chang Wook Jeong; Yong Hyun Park; Sung Ii Hwang; Sangchul Lee; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Hak Jong Lee; Sang Eun Lee Journal: Prostate Int Date: 2014-12-30
Authors: Joo Yong Lee; Dae Hun Lee; Nam Hoon Cho; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Seung Choul Yang; Kang Su Cho Journal: Yonsei Med J Date: 2014-03 Impact factor: 2.759